1. Volume 69, Issue 1, Pages 149-156 (January 2016)
A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy 
Eduard Baco, Erik Rud, Lars Magne Eri, Gunnar Moen, Ljiljana Vlatkovic, Aud Svindland, Heidi B. Eggesbø, Osamu Ukimura 
European Urology 
Volume 69, Issue 1, Pages (January 2016)
DOI: /j.eururo
Copyright © 2015 European Association of Urology Terms and Conditions

2. Fig. 1
Study flow diagram.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions

3. Fig. 2
Results for a 59-yr-old man with prostate-specific antigen of 7.6 ng/ml, a normal digital rectal examination, and a prostate volume of 50ml. The patient had a positive family history of metastatic prostate cancer (his father). Prebiopsy magnetic resonance imaging, in terms of (A) a T2-weighed image, (B) a T2-weighted image with superimposed b2000, and (C) an apparent diffusion coefficient map with color overlay, was normal. (D,E) A 12-core random biopsy revealed Gleason 4+5 and 5+4 prostate cancer in the paramedial left prostate base and mid gland (demonstrated in three-dimensional registered biopsy needle trajectories; UroStation). Positive cores are registered as red bars; the cancer core length was 4 and 3mm (50% and 37% cancer core invasion). Green bars represent negative cores. The patient was treated with radical prostatectomy. (F) Histologic analysis of a step-sectioned prostate specimen confirmed pT3 Gleason 5+4 prostate cancer with neuroendocrine differentiation localized in the central and peripheral zone. The tumor dimensions were 27mm × 16mm × 16mm (3.5ml) and the tumor location corresponded to the three-dimensional location of positive cores.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions

4. Fig. 3
Results for a 67-yr-old man with prostate-specific antigen of 7.2 ng/ml, a normal digital rectal examination, and a prostate volume of 75ml. Prebiopsy magnetic resonance imaging (MRI) suggested anterior prostate cancer visible on (A) axial T2-weighted images and (B) an apparent diffusion coefficient map with color overlay (arrows). MRI/transrectal ultrasound (TRUS)-targeted biopsy (red bars), as demonstrated by (C) axial and (D) sagittal MRI/TRUS fused images, revealed Gleason 3+4 prostate cancer. The cancer core length was 9 and 5mm (53% and 45% cancer core invasion). The patient was treated with radical prostatectomy. (E) A step-sectioned prostate specimen confirmed pT2 Gleason 3+4 prostate cancer. The tumor dimensions were 20mm × 17mm × 12mm (2.2ml) in the right anterior mid-gland region. (F) Positive biopsies (red bars) and the targeted region (yellow circle) shown in (C) and (D) corresponded to the three-dimensional tumor location in segment 10p.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions